316 related articles for article (PubMed ID: 27738323)
1. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
2. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
3. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
4. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
5. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.
Gao L; Gao M; Yang G; Tao Y; Kong Y; Yang R; Meng X; Ai G; Wei R; Wu H; Wu X; Shi J
Biomed Res Int; 2015; 2015():459052. PubMed ID: 26000292
[TBL] [Abstract][Full Text] [Related]
7. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
[TBL] [Abstract][Full Text] [Related]
11. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Che F; Ye X; Wang Y; Ma S; Wang X
Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP; Moreau P; San-Miguel JF; Richardson PG
Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells.
Shalem-Cohavi N; Beery E; Nordenberg J; Rozovski U; Raanani P; Lahav M; Uziel O
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117293
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
15. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
16. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
19. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Catley L; Weisberg E; Kiziltepe T; Tai YT; Hideshima T; Neri P; Tassone P; Atadja P; Chauhan D; Munshi NC; Anderson KC
Blood; 2006 Nov; 108(10):3441-9. PubMed ID: 16728695
[TBL] [Abstract][Full Text] [Related]
20. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
